TARS1 and pancreatic neoplasm: For example, methionyl-tRNA synthetase (MARS) and threonyl-tRNA synthetase (TARS) overexpression has been associated with poor clinical outcomes in lung cancer [13] and pancreatic cancer [14], respectively.